At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 329 enrolled
Drug / intervention
AZD3199 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-week, Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group, Multi-centre Study to Assess the Efficacy and Tolerability/Safety of Inhaled AZD3199 Once Daily Compared to 9 μg Formoterol Bid and Placebo in Patients With Moderate to Severe COPD
In Brief
A Phase 2 clinical trial evaluating AZD3199, formoterol, and 1 other intervention for COPD. Completed, enrolled 329 participants across 38 sites in 5 countries.
Detailed Summary
The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesBulgaria, Canada, Japan, Poland, Russia
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJun 2009
Primary CompletionMar 2010
TodayJul 2026
First PostedJun 29, 2009
Enrollment StartJun 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.0 years ago
Interventions
AZD3199drug
Dry powder for inhalation, o.d., 4 weeks
formoteroldrug
Dry powder for inhalation, b.i.d., 4 weeks
Placebodrug
Dry powder for inhalation, b.i.d., 4 weeks